Denosumab and Renal Function

Advantages of Denosumab in Renal Impairment

Denosumab is preferred over bisphosphonates in patients with impaired renal function as it does not require dose adjustment for renal impairment and has fewer adverse events related to renal toxicity 1, 2, 3
Unlike bisphosphonates, denosumab does not require monitoring of renal function or dose adjustments for patients with impaired renal function 3, 4
Denosumab is the agent of choice in patients with renal impairment (creatinine clearance <60 ml/min) 5
Recent data comparing denosumab with zoledronic acid demonstrates fewer adverse events related to renal toxicity with denosumab 1

Serum calcium must be measured before starting denosumab, as hypocalcemia is more common with denosumab (13%) than with zoledronic acid (6%) 4
Vitamin D levels should be evaluated before starting therapy to ensure adequate levels 4
A comprehensive dental examination is mandatory before initiating denosumab to reduce the risk of osteonecrosis of the jaw 4

Unlike bisphosphonates, serum creatinine does not need to be monitored before each dose of denosumab 3
Regular monitoring of serum calcium is necessary, especially after the first few doses, to detect hypocalcemia 4
Vitamin D status should be evaluated intermittently during treatment 4
Oral health should be closely monitored throughout treatment to detect early signs of osteonecrosis of the jaw 4

Calcium supplementation (500-1000 mg/day) is required during denosumab treatment 4
Vitamin D supplementation should be administered alongside calcium 4
Hypocalcemia must be corrected before starting denosumab 4

Denosumab should not be stopped abruptly given its reversible mechanism of action 1, 3
If denosumab is discontinued for more than 6 months, bisphosphonate treatment is recommended to suppress rebound osteolysis 5